Figure 2).

Relative potencies of different hepatitis B antivirals at 48 to 52 weeks of therapy. Lamivudine has been compared with entecavir (105) and telbivudine (118) in two separate, randomized, controlled trials. Tenofovir was compared with adefovir followed by open-label tenofovir in separate, randomized, clinical trials. A Proportion of patients with hepatitis B virus (HBV) DNA <80 IU/mL. B Mean log₁₀ IU/mL decline in HBV DNA levels. Anti-HBe Hepatitis B e antibody; HBeAg Hepatitis B e antigen